SION
Sionna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.18
+6.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 306.0K | 647.0K | 668.0K | — | — |
| Gross Profit | (306.0K) | (647.0K) | (668.0K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 72.0M | 60.3M | 57.3M | 40.6M | 34.6M |
| SG&A Expense | 38.2M | 28.7M | 13.3M | 9.7M | 6.8M |
| General & Admin Expense | 38.4M | 28.7M | 13.3M | 9.7M | 6.8M |
| Selling & Marketing Expense | (154.0K) | — | — | — | — |
| Other Expenses | (1.1M) | (647.0K) | (668.0K) | — | — |
| Total Operating Expenses | 109.2M | 88.3M | 69.9M | 50.3M | 41.4M |
| Cost and Expenses | 109.5M | 89.0M | 70.6M | 50.3M | 41.4M |
| Operating Income (EBIT) | (109.5M) | (89.0M) | (70.6M) | (50.3M) | (41.4M) |
| Non-Operating | |||||
| Interest Income | 12.0M | 13.3M | 8.2M | 2.8M | 1.1M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 12.0M | 13.3M | 8.2M | 2.8M | 1.1M |
| Other Non-Op Income/Expense | 12.1M | 13.7M | 8.9M | 3.1M | 1.1M |
| Non-Operating Income (excl Interest) | (15.3M) | (13.7M) | (8.9M) | (3.1M) | (1.1M) |
| EBT (Pre-Tax Income) | (97.4M) | (75.3M) | (61.7M) | (47.3M) | (40.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (97.4M) | (75.3M) | (61.7M) | (47.3M) | (40.2M) |
| Earnings from Cont. Ops | (97.4M) | (75.3M) | (61.7M) | (47.3M) | (40.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (97.4M) | (75.3M) | (61.7M) | (47.3M) | (40.2M) |
| Per Share | |||||
| Basic EPS | ($2.18) | ($1.88) | ($1.40) | ($1.07) | ($0.91) |
| Diluted EPS | ($2.18) | ($1.88) | ($1.40) | ($1.07) | ($0.91) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 45.1M | 40.0M | 44.1M | 44.1M | 44.1M |
| Diluted Shares Outstanding | 45.1M | 40.0M | 44.1M | 44.1M | 44.1M |
| Profitability Metrics | |||||
| EBITDA | (93.0M) | (74.6M) | (61.0M) | (46.7M) | (40.1M) |
| D&A | 1.2M | 647.0K | 668.0K | 583.0K | 122.0K |
| EBIT | (94.2M) | (75.3M) | (61.7M) | (47.3M) | (40.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026